InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three US Patents Page 1

• InMed’s intellectual property portfolio comprises a total of 13 patent families covering novel chemical entities, formulations, methods of manufacture and methods of use

Vancouver, British Columbia–(Newsfile Corp. – August 21, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical need, today announced that it has been granted three U.S. patents: one covering a formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one covering biosynthetic manufacturing processes, and one covering a formulation for ocular drug delivery.

The method of use patent, entitled “Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders,” covers the drug candidate INM-755 which has completed a Phase 2 clinical trial in the treatment of symptoms related to epidermolysis bullosa. The patent is now issued in the U.S., Australia, Japan and Israel and is pending in several other jurisdictions. The biosynthesis patent for the production of proprietary analogues for our drug development programs is issued in the U.S. Additionally, a patent on the formulation and use of ocular drugs is issued/allowed in the U.S., Europe, Australia, Japan and India and is also pending in other jurisdictions.